Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2025.41025
Abstract: Key Points Question How does cladribine compare with sphingosine-1-phosphate receptor modulators (S1PRMs) in treatment-naive patients with relapsing-remitting multiple sclerosis? Findings In this comparative effectiveness research study of 950 propensity score–matched treatment-naive patients with at least… read more here.
Keywords: treatment; cladribine; relapsing remitting; comparative effectiveness ... See more keywords
Cladribine effects on T and B cells and T cell reactivity in multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2023 at "Annals of neurology"
DOI: 10.1002/ana.26684
Abstract: OBJECTIVES Cladribine tablet therapy is an efficacious treatment for multiple sclerosis (MS), however, its mechanism of action on T and B cell subsets remains unclear. The purpose of this study was to investigate the treatment… read more here.
Keywords: cell; cladribine; reactivity; treatment ... See more keywords
Cladribine‐ and decitabine‐containing conditioning regimen has a low post‐transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Cancer"
DOI: 10.1002/ijc.34419
Abstract: To reduce the risk of relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), there have been continuing efforts to optimize the conditioning regimens. Our study aimed to analyze the risk factors associated with the relapse… read more here.
Keywords: aml high; cladribine; high risk; relapse ... See more keywords
Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04800-3
Abstract: Hairy cell leukemia (HCL) is a rare hematologic disorder characterized by pancytopenia and splenomegaly for which a single course of cladribine is highly effective in inducing complete remissions. However, there is limited real-world data on… read more here.
Keywords: cladribine; hairy cell; treated cladribine; cell leukemia ... See more keywords
Toxidermies et leucémie à tricholeucocytes : une association non fortuite
Sign Up to like & getrecommendations! Published in 2019 at "Annales De Dermatologie Et De Venereologie"
DOI: 10.1016/j.annder.2019.09.205
Abstract: Introduction La leucemie a tricholeucocytes (LT) est une forme rare de leucemie, dont un des traitements de 1ere intention est la cladribine. Des toxidermies au cours des LT ont ete rapportees, attribuees a la cladribine… read more here.
Keywords: avec; cladribine; sensibilisation; chez patients ... See more keywords
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2018.12.015
Abstract: PURPOSE We applied Multi-Criteria Decision Analysis (MCDA) methods in a structured benefit-risk assessment of cladribine and newer approved disease-modifying drugs (DMDs) for patients with relapsing-remitting multiple sclerosis (RRMS). METHODS Decision conferencing with clinical neurologists as… read more here.
Keywords: decision; risk; cladribine; patients rrms ... See more keywords
Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.
Sign Up to like & getrecommendations! Published in 2019 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2018.10.006
Abstract: BACKGROUND There has been long-term interest in cladribine as a drug for the treatment of MS. The current study focused on the effect of cladribine on oligoclonal bands (OCB) expression in the CSF in relapsing-remitting… read more here.
Keywords: cladribine; oligoclonal bands; treatment; study ... See more keywords
An update on cladribine for relapsing-remitting multiple sclerosis
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2017.1372747
Abstract: ABSTRACT Introduction: Despite recent progress, currently available therapies for relapsing remitting multiple sclerosis (MS) are only partly effective, and their use is limited by tolerability and safety issues, as well as high cost. Cladribine was… read more here.
Keywords: relapsing remitting; cladribine; treatment; multiple sclerosis ... See more keywords
Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B‐cell non‐Hodgkin lymphoma and previously untreated mantle cell lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.16008
Abstract: Altered DNA methylation and histone acetylation in lymphoma provided the rationale for using vorinostat (SAHA), cladribine and rituximab (SCR) in non‐Hodgkin lymphomas (NHL) in this phase 1–2 study (NCT00764517). Treatment included cladribine 5 mg/m2 intravenously… read more here.
Keywords: lymphoma; phase; cladribine; previously untreated ... See more keywords
Cladribine monotherapy in a patient with coexisting Crohn's disease and multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2025 at "Multiple sclerosis"
DOI: 10.1177/13524585251390859
Abstract: Patients with coexisting Crohn's disease (CD) and multiple sclerosis (MS) present a complex therapeutic challenge, especially when standard dual-purpose therapies such as anti-integrins or S1P receptor modulators are contraindicated. We report the first case of… read more here.
Keywords: multiple sclerosis; cladribine; crohn disease; coexisting crohn ... See more keywords
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Annals of hematology"
DOI: 10.1182/blood-2022-163650
Abstract: We sought to evaluate the efficacy of the purine analogue cladribine in 79 patients with advanced systemic mastocytosis (AdvSM) using data from the 'German Registry on Disorders of Eosinophils and Mast Cells (GREM)'. The overall… read more here.
Keywords: cladribine patients; cladribine; patients advanced; systemic mastocytosis ... See more keywords